Construction Business Review Conferences

Southeast Asia's expanding biotechnology and pharmaceutical sectors are creating new requirements for laboratory infrastructure and analytical capabilities.

Pharmaceutical companies are under pressure to demonstrate measurable results from artificial intelligence investments as digital initiatives move beyond experimental projects.

Westlake Village, California: Clinical trial organizations are navigating a rapidly changing development environment as artificial intelligence, evolving regulatory expectations, decentralized approaches, and new operating models.

Westlake Village, California: Pharmaceutical marketing is undergoing a significant transformation as artificial intelligence, changing patient behaviors, evolving payer expectations.

Seoul, South Korea: South Korea’s expanding biopharmaceutical manufacturing ecosystem is creating a growing need for technologies that can improve productivity, process consistency, and manufacturing scalability.

Ho Chi Minh City, Vietnam: Southeast Asia’s biologics industry is entering a period of expanding research, manufacturing, and investment activity as biopharma companies strengthen regional capabilities and pursue new opportunities.

Shanghai and Wuxi, China: As life sciences companies increasingly pursue international growth, access to capital is becoming closely linked with strategic partnerships, clinical development, regulatory expertise, and market access.

Boston, MA: The development of complement-targeted therapies is entering a new phase as researchers and biopharmaceutical companies expand beyond established pathways to explore broader clinical applications.

Scientific progress does not always provide a clear route from a promising asset to a viable development program.

CNS drug development depends increasingly on identifying biological signals that can support patient selection and provide earlier evidence of therapeutic activity.